NCT07157085

Brief Summary

We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma. The resulting tool will be prospectively deployed to guide personalized surgical, TACE, and systemic therapy decisions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2008

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
16 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

August 28, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 5, 2025

Completed
Last Updated

September 5, 2025

Status Verified

August 1, 2025

Enrollment Period

16 years

First QC Date

August 28, 2025

Last Update Submit

August 28, 2025

Conditions

Hepatocellular Carcinoma (HCC)

Keywords

HCCartificial intelligencemultitask deep learningclinical decision support

Outcome Measures

Primary Outcomes (1)

  • Overall Survival

    from diagnosis of HCC to death or last follow-up

    60 months

Secondary Outcomes (1)

  • Progression-free survival

    60 months

Interventions

Comprehensive treatmentOTHER

Comprehensive HCC therapies include liver resection, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with HCC received comprehensive therapies such as liver resection, ablation, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy

You may qualify if:

  • age 18-75 years;
  • HCC diagnosed according to the European Association for the Study of the Liver/American Association for the Study of Liver Diseases criteria)
  • Eastern Cooperative Oncology Group performance status \< 2;
  • Child-Pugh class A or B liver function;

You may not qualify if:

  • HCC combined with other malignancies;
  • missing image data during perioperative period;
  • lost to follow-up \> 12 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Guangzhou, Guangdong, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Diagnostic liver biopsy specimens and postoperative surgical specimens obtained from the patient

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 28, 2025

First Posted

September 5, 2025

Study Start

January 1, 2008

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

September 5, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)